January 1, 2009Platelets
Cross validation of aspirin effect in healthy individuals by Impact-R and PFA-100: A double blind randomized placebo controlled trial
Why the study?
Does aspirin 160 mg per day alter platelet function measured by Impact-R and PFA-100 compared to placebo in healthy male individuals?
Population
37 healthy male individuals (n=17 randomized to aspirin, n=20 age-matched controls for placebo)
Comparison
Aspirin 160 mg per day for 7-10 days vs Placebo for 7-10 days
Design
RCT, randomized, double blind
Follow-up
7-10 days
Authors
Discussion
Loading...
Member takes
Implication
Both tests detect aspirin's antiplatelet effect; confirms utility of each while highlighting discordance that limits interchangeability.
Structured PICO
Does aspirin 160 mg per day alter platelet function measured by Impact-R and PFA-100 compared to placebo in healthy male individuals?
P
Population
37 healthy male individuals (n=17 randomized to aspirin, n=20 age-matched controls for placebo)
I
Intervention
Aspirin 160 mg per day for 7-10 days
C
Comparator
Placebo for 7-10 days
O
Outcome
Aspirin response measured by high shear-induced platelet adhesion to polystyrene after pre-incubation with arachidonic acid (Impact-R) and closure time of collagen/epinephrine cartridges (PFA-100 CEPI-CT) at 7-10 dayssurrogate
Both Impact-R and PFA-100 can demonstrate the antiplatelet effect of aspirin in healthy individuals, but the tests show significant discordance.
Limitations
- trial design cannot provide data on the specificity of the different tests
Cite This Study
Gouya et al. (2009) studied this question.